Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADS-5102 Safety and Efficacy in MS Walking Impairment Extension Study
NCT03567057Phase 3Completed
- Start
- Jul 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of amantadine in multiple sclerosis (MS). Started Jul 2018; status: completed.
02
Drugs
amantadine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03567057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03567057.